All In Biotech

Drug Trial Radar · NCT06547385

Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

ONO-4578 Phase I Study An Open-label, Uncontrolled Study of First-line Combination Therapy of ONO-4578 and ONO-4538 With Standard Therapy XELOX Plus Bevacizumab or FOLFOX Plus Bevacizumab in Patients With Unresectable, Advanced or Recurrent Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Actual

Start

Jan 13, 2021

Primary completion

Oct 31, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.

Conditions

  • Colorectal Cancer

Interventions

  • ONO-4578Drug

    Specified dose on specified days

  • ONO-4538Drug

    Specified dose on specified days

  • CapecitabineDrug

    Specified dose on specified days

  • OxaliplatinDrug

    Specified dose on specified days

  • FluorouracilDrug

    Specified dose on specified days

  • Calcium Levofolinate HydratebDrug

    Specified dose on specified days

  • BevacizumabDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of AEs and SAEsTime frame: up to 3years
  2. Incidence and severity of clinical laboratory abnormalitiesTime frame: up to 3years
  3. 12-lead electrocardiography (Heart rate)Time frame: up to 3years
  4. 12-lead electrocardiography (PR interval)Time frame: up to 3years
  5. 12-lead electrocardiography (RR interval)Time frame: up to 3years
  6. 12-lead electrocardiography (QRS width)Time frame: up to 3years
  7. 12-lead electrocardiography (QT interval)Time frame: up to 3years
  8. Chest X-ray testTime frame: up to 3years
  9. ECOG performance statusTime frame: up to 3years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan

  • Kobe City Hospital Organization Kobe City Medical Center General Hospital

    Kobe, Hyōgo, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Saitama Cancer Center

    Ina, Kitaadati-gun, Saitama, Japan

  • NHO Osaka National Hospital

    Osaka, Osaka, Japan

  • Osaka General Medical Center

    Osaka, Osaka, Japan

  • Osaka Medical and Pharmaceutical University Hospital

    Takatsuki-shi, Osaka, Japan

  • Saitama Medical University International Medical Center

    Hidaka-shi, Saitama, Japan

  • Cancer Institute Hospital of JFCR

    Koto-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.